

Diagnosis and Treatment of Overactive Bladder (Non-N Guideline Amendment

Journal of Urology

193, 1572-1580

DOI: [10.1016/j.juro.2015.01.087](https://doi.org/10.1016/j.juro.2015.01.087)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of Overactive Bladder Refractory to Medical Therapy. Current Bladder Dysfunction Reports, 2014, 9, 336-340.	0.2	1
2	New evidence in the treatment of overactive bladder. Current Opinion in Obstetrics and Gynecology, 2015, 27, 366-372.	0.9	8
4	Sacral Nerve Stimulation for Pediatric Lower Urinary Tract Dysfunction: Development of a Standardized Pathway with Objective Urodynamic Outcomes. Journal of Urology, 2015, 194, 1721-1727.	0.2	25
5	Treatment of Overactive Bladder in the Elderly Female: The Case for Trosipium, Oxybutynin, Fesoterodine and Darifenacin. Drugs and Aging, 2015, 32, 809-819.	1.3	20
6	Current and potential urological applications of botulinum toxin A. Nature Reviews Urology, 2015, 12, 519-533.	1.9	31
7	Overactive Bladder and the β_3 -Adrenoceptor Agonists: Current Strategy and Future Prospects. Drugs, 2015, 75, 1707-1713.	4.9	7
8	Early investigational β_3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opinion on Investigational Drugs, 2015, 24, 1299-1306.	1.9	13
9	Clinical Pathways of Third-Line Treatment of Overactive Bladder in the Elderly. Current Bladder Dysfunction Reports, 2015, 10, 381-390.	0.2	0
11	Botulinum toxin A for the Treatment of Overactive Bladder. Toxins, 2016, 8, 59.	1.5	39
12	Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery. Toxins, 2016, 8, 91.	1.5	16
13	Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder. Journal of the American Geriatrics Society, 2016, 64, 779-787.	1.3	23
14	Evaluation and Management of Lower Urinary Tract Symptoms After Outlet Surgery for Benign Prostatic Hyperplasia. Current Bladder Dysfunction Reports, 2016, 11, 242-247.	0.2	4
15	Underactive bladder in women. Current Opinion in Urology, 2016, 26, 309-314.	0.9	7
16	Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder. Neurourology and Urodynamics, 2016, 35, 1028-1033.	0.8	9
17	Neuromodulation and female pelvic disorders. Current Opinion in Urology, 2016, 26, 321-327.	0.9	10
18	Urodynamic Evaluation Following Bladder Reconstruction. Current Bladder Dysfunction Reports, 2016, 11, 300-309.	0.2	2
19	Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation. Urology, 2016, 94, 57-63.	0.5	108
20	Overactive Bladder. , 2016, , 251-268.		0

#	ARTICLE	IF	CITATIONS
21	Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States. <i>Urology</i> , 2016, 87, 64-69.	0.5	23
22	Urinary incontinence in men: current and developing therapy options. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 715-726.	0.9	4
23	Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2016, 48, 1215-1227.	0.6	24
24	Anticholinergic medication use and dementia: latest evidence and clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2016, 7, 217-224.	1.0	53
25	A liquid chromatography-tandem mass spectrometry method for the quantitation of imidafenacin in human plasma: application to a clinical pharmacokinetic study. <i>Analytical Methods</i> , 2016, 8, 6903-6908.	1.3	1
26	Posible mecanismo de acción de la neuromodulación tibial en la hiperactividad del detrusor. Papel de las interneuronas. <i>Revista Mexicana De Urologia</i> , 2016, 76, 229-236.	0.0	2
27	Urodynamic findings in women with refractory overactive bladder symptoms. <i>International Journal of Urology</i> , 2016, 23, 75-79.	0.5	23
28	Editorial Comment to Urodynamic findings in women with refractory overactive bladder symptoms. <i>International Journal of Urology</i> , 2016, 23, 79-79.	0.5	0
29	The Overactive Bladder and the AUA Guidelines: A Proposed Clinical Pathway for Evaluation and Effective Management in a Contemporary Urology Practice. <i>Urology Practice</i> , 2016, 3, 399-405.	0.2	4
30	Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. <i>The Cochrane Library</i> , 0, , .	1.5	2
31	Differences in the Association of Nocturia and Functional Outcomes of Sleep by Age and Gender: A Cross-sectional, Population-based Study. <i>Clinical Therapeutics</i> , 2016, 38, 2386-2393.e1.	1.1	17
32	Tibial nerve stimulation to inhibit the micturition reflex by an implantable wireless driver microstimulator in cats. <i>Medicine (United States)</i> , 2016, 95, e4537.	0.4	1
33	Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. <i>Journal of Medical Economics</i> , 2016, 19, 1135-1143.	1.0	23
34	Evaluation and Management of Mid-Urethral Sling Complications. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 160-168.	0.2	2
36	The Burden of Overactive Bladder on US Public Health. <i>Current Bladder Dysfunction Reports</i> , 2016, 11, 8-13.	0.2	93
37	Diagnosis and Management of Lower Urinary Tract Dysfunction. <i>Surgical Clinics of North America</i> , 2016, 96, 441-452.	0.5	8
38	The role of acupuncture in managing overactive bladder; a review of the literature. <i>International Urogynecology Journal</i> , 2016, 27, 1645-1651.	0.7	20
39	Use of Botulinum Toxin in Urologic Diseases. <i>Urology</i> , 2016, 91, 21-32.	0.5	16

#	ARTICLE	IF	CITATIONS
40	An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Therapeutic Advances in Urology, 2016, 8, 83-90.	0.9	16
41	Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. Current Medical Research and Opinion, 2016, 32, 787-796.	0.9	14
42	Conjoint Urological Society of Australia and New Zealand (<scp>USANZ</scp>) and Urogynaecological Society of Australasia (<scp>UGSA</scp>) Guidelines on the management of adult non-€urogenic overactive bladder. BJU International, 2016, 117, 34-47.	1.3	28
43	Overactive Bladder. Obstetrics and Gynecology Clinics of North America, 2016, 43, 59-68.	0.7	44
44	Prevention of pelvic floor disorders: international urogynecological association research and development committee opinion. International Urogynecology Journal, 2016, 27, 1785-1795.	0.7	32
45	Delivery methods for drugs used in the treatment of overactive bladder. Expert Opinion on Drug Delivery, 2016, 13, 361-371.	2.4	2
46	Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. International Urology and Nephrology, 2016, 48, 19-30.	0.6	36
47	Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome. Neurourology and Urodynamics, 2017, 36, 727-733.	0.8	26
48	Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement. World Journal of Urology, 2017, 35, 299-306.	1.2	8
49	Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. Neurourology and Urodynamics, 2017, 36, 338-343.	0.8	6
50	Stimulation latency and comparison of cycling regimens in women using sacral neuromodulation. Neurourology and Urodynamics, 2017, 36, 486-489.	0.8	12
51	Can botox improve night-time overactive bladder symptoms in women?. Neurourology and Urodynamics, 2017, 36, 648-652.	0.8	10
52	A comparative study of electroacupuncture at Zhongliao (BL33) and other acupoints for overactive bladder symptoms. Frontiers of Medicine, 2017, 11, 129-136.	1.5	21
53	Pathophysiology of Overactive Bladder: Current Understanding. Current Bladder Dysfunction Reports, 2017, 12, 74-79.	0.2	9
54	Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis. BMJ Open, 2017, 7, e013225.	0.8	8
55	Cognitive Effects of Anticholinergics in the Geriatric Patient Population: Safety and Treatment Considerations. Current Bladder Dysfunction Reports, 2017, 12, 104-111.	0.2	1
56	A Systematic Approach to the Evaluation and Management of the Failed Artificial Urinary Sphincter. Current Urology Reports, 2017, 18, 18.	1.0	9
57	The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Na~ve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. Journal of Urology, 2017, 198, 167-175.	0.2	27

#	ARTICLE	IF	CITATIONS
58	Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1064-1070.	1.0	5
59	Current treatment of pelvic organ prolapse correlated with chronic pelvic pain, bladder and bowel dysfunction. <i>Current Opinion in Urology</i> , 2017, 27, 274-281.	0.9	27
60	Sacral Neuromodulation for the Treatment of Pelvic Floor Disorders. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 26-34.	0.2	0
61	Potential of <i>Bryophyllum pinnatum</i> as a Detrusor Relaxant: An in Vitro Exploratory Study. <i>Planta Medica</i> , 2017, 83, 1274-1280.	0.7	12
62	Management of device-related complications after sacral neuromodulation for lower urinary tract disorders in women: a single center experience. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 951-957.	0.8	12
63	Combination of sacral nerve and tibial nerve stimulation for treatment of bladder overactivity in pigs. <i>International Urology and Nephrology</i> , 2017, 49, 1139-1145.	0.6	3
64	Overactive Bladder Is Strongly Associated With Frailty in Older Individuals. <i>Urology</i> , 2017, 106, 26-31.	0.5	47
65	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICIERS 2015). <i>Neurourology and Urodynamics</i> , 2017, 36, 882-893.	0.8	44
66	Sex difference in the contribution of GABA _B receptors to tibial neuromodulation of bladder overactivity in cats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 312, R292-R300.	0.9	8
67	Stimulation of the pelvic nerve increases bladder capacity in the prostaglandin E ₂ rat model of overactive bladder. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F657-F665.	1.3	14
68	Patient Satisfaction on Overactive Bladder Treatment. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 58-65.	0.2	1
69	Nonsurgical Management of Urinary Incontinence in Older Women. <i>Current Geriatrics Reports</i> , 2017, 6, 54-63.	1.1	0
70	The role of nonpharmacologic therapies in management of chronic pelvic pain: what to do when surgery fails. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 231-239.	0.9	20
71	Sacral neuromodulation of nociceptive bladder overactivity in cats. <i>Neurourology and Urodynamics</i> , 2017, 36, 1270-1277.	0.8	13
72	Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias. <i>Pharmacotherapy</i> , 2017, 37, 673-683.	1.2	11
73	Physiotherapy and behavior therapy for the treatment of overactive bladder syndrome: a prospective cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1211-1217.	0.8	8
74	Estimulación transcutánea del nervio tibial posterior en el tratamiento de la incontinencia urinaria de urgencia refractaria, de origen idiopático y neuropático. <i>Actas Urológicas Españolas</i> , 2017, 41, 465-470.	0.3	23
76	Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. <i>Journal of Medical Economics</i> , 2017, 20, 614-622.	1.0	10

#	ARTICLE	IF	CITATIONS
77	Complications of Female Incontinence and Pelvic Reconstructive Surgery. <i>Current Clinical Urology</i> , 2017, , .	0.0	0
78	Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction. <i>Expert Review of Medical Devices</i> , 2017, 14, 3-14.	1.4	22
79	Re: Chen H. et al: Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial (<i>Urology</i> 2016;100:59-64). <i>Urology</i> , 2017, 101, 177.	0.5	0
80	OnabotulinumtoxinA for Overactive Bladder and Urinary Incontinence. <i>Journal of Urology</i> , 2017, 197, S224-S225.	0.2	3
81	Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis. <i>Archives of Gerontology and Geriatrics</i> , 2017, 69, 77-96.	1.4	56
82	Desmopressin acetate nasal spray for adults with nocturia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1281-1293.	1.3	13
83	Urinary Incontinence in Women. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1592.	3.8	273
84	Nocturia is Associated with Poor Sleep Quality Among Older Women in the Study of Osteoporotic Fractures. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2502-2509.	1.3	14
85	AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2017, 23, 177-178.	0.6	32
86	Establishing a Multidisciplinary Approach to the Management of Neurologic Disease Affecting the Urinary Tract. <i>Urologic Clinics of North America</i> , 2017, 44, 377-389.	0.8	7
87	Incidence and Management of Lower Urinary Tract Symptoms After Urethral Stricture Repair. <i>Current Urology Reports</i> , 2017, 18, 70.	1.0	2
88	Transcutaneous stimulation of the posterior tibial nerve for treating refractory urge incontinence of idiopathic and neurogenic origin. <i>Actas Urológicas Españolas (English Edition)</i> , 2017, 41, 465-470.	0.2	7
89	Room to Grow? What is the Current Role of Neuromodulation in Pediatric Bowel-Bladder Dysfunction?. <i>Journal of Urology</i> , 2017, 198, 498-499.	0.2	0
90	Editorial Comment. <i>Journal of Urology</i> , 2017, 198, 210-210.	0.2	0
91	Editorial Comment. <i>Urology</i> , 2017, 106, 30-31.	0.5	0
92	Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. <i>Therapeutic Advances in Urology</i> , 2017, 9, 137-154.	0.9	43
93	The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States. <i>Journal of Medical Economics</i> , 2017, 20, 1272-1280.	1.0	5
94	Trends in Ambulatory Management of Urinary Incontinence in Women in the United States. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2017, 23, 250-255.	0.6	12

#	ARTICLE	IF	CITATIONS
95	Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2017, 23, 8-12.	0.6	6
96	Clinical Factors to Decide Between Sacral Neuromodulation and Onabotulinum Toxinâ€”When Is One Clearly Better?. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 328-336.	0.2	0
98	Evaluating the efficacy and tolerability of mirabegron, a Î²3-adrenoceptor agonist, for the treatment of overactive bladder: Systematic review and network meta-analysis. <i>Journal of Clinical Urology</i> , 2017, 10, 557-567.	0.1	2
99	Percutaneous Tibial Nerve Stimulation Therapy for Overactive Bladder Syndrome: Clinical Effectiveness, Urodynamic, and Durability Evaluation. <i>Urology</i> , 2017, 108, 52-58.	0.5	23
100	CE. <i>American Journal of Nursing</i> , 2017, 117, 34-41.	0.2	2
101	Where Are We Headed with Neuromodulation for Overactive Bladder?. <i>Current Urology Reports</i> , 2017, 18, 59.	1.0	12
103	Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis. <i>Urology</i> , 2017, 100, 53-58.	0.5	25
104	Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment. <i>Neurourology and Urodynamics</i> , 2017, 36, 1377-1381.	0.8	18
106	The impact of prior back surgery on neuromodulation outcomes: A review of over 500 patients. <i>Neurourology and Urodynamics</i> , 2017, 36, 1535-1542.	0.8	8
107	Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB. <i>Neurourology and Urodynamics</i> , 2017, 36, 1564-1569.	0.8	16
108	Intravesical Botulinum Toxin for Neurogenic Bladderâ€”Can We Just Irrigate the Bladder with Botulinumtoxin?. <i>Current Bladder Dysfunction Reports</i> , 2017, 12, 343-348.	0.2	0
109	Urge Incontinence: Updates in Non-pharmacologic Treatments. <i>Current Obstetrics and Gynecology Reports</i> , 2017, 6, 257-262.	0.3	0
110	Urinary Microbiome and Psychological Factors in Women with Overactive Bladder. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 488.	1.8	79
111	Urogynecological conditions associated with overactive bladder symptoms in women. <i>Canadian Urological Association Journal</i> , 2017, 11, 83.	0.3	6
112	An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents. <i>BMC Geriatrics</i> , 2017, 17, 295.	1.1	4
113	Schooling impacts on the overactive bladder diagnosis in women. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 1129-1135.	0.7	0
114	Correlation between overactive bladder symptom score and neuropsychological parameters in Alzheimerâ€™s disease patients with lower urinary tract symptom. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 256-263.	0.7	9
115	Recent advances in pharmacological management of urinary incontinence. <i>F1000Research</i> , 2017, 6, 2148.	0.8	4

#	ARTICLE	IF	CITATIONS
116	Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal, 2017, 11, 123.	0.3	10
117	Bladder Dysfunction and Urinary Incontinence After the Menopause: Hormones, Drugs, or Surgery?. ISGE Series, 2018, , 287-292.	0.2	0
118	Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings. Current Medical Research and Opinion, 2018, 34, 1771-1776.	0.9	12
119	A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder. International Urogynecology Journal, 2018, 29, 1213-1219.	0.7	19
120	The history of the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction. Neurourology and Urodynamics, 2018, 37, 2015-2025.	0.8	1
122	Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourology and Urodynamics, 2018, 37, 1667-1671.	0.8	4
123	Medical treatment of female overactive bladder syndrome and treatment-related effects. Journal of the Formosan Medical Association, 2018, 117, 871-878.	0.8	10
124	Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects. Therapeutic Advances in Urology, 2018, 10, 165-173.	0.9	40
125	International Continence Society best practice statement for use of sacral neuromodulation. Neurourology and Urodynamics, 2018, 37, 1823-1848.	0.8	113
126	Adult and Pediatric Neuromodulation. , 2018, , .		2
127	Overactive Bladder: Advancement or More of the Same. European Urology, 2018, 73, 791-792.	0.9	0
128	Pre-Menopause, Menopause and Beyond. ISGE Series, 2018, , .	0.2	7
129	Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary. Neurourology and Urodynamics, 2018, 37, 1701-1710.	0.8	5
130	Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis. Journal of Obstetrics and Gynaecology Research, 2018, 44, 524-531.	0.6	7
131	Female Voiding Dysfunction and Urinary Incontinence. Medical Clinics of North America, 2018, 102, 313-324.	1.1	9
132	Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature. International Urogynecology Journal, 2018, 29, 1081-1091.	0.7	16
133	Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 324-333.	0.9	151
134	Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA. Current Bladder Dysfunction Reports, 2018, 13, 25-30.	0.2	1

#	ARTICLE	IF	CITATIONS
135	Adaptation of evidence-based guideline recommendations to address urinary incontinence in nursing home residents according to the ADAPTE process. <i>Journal of Clinical Nursing</i> , 2018, 27, 2974-2983.	1.4	10
136	The Antimuscarinic Agent Tolterodine Regulates Bladder Extracellular Matrix in Partial Bladder Outlet Obstruction in Rats. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 36-45.	1.1	9
137	Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men. <i>International Urology and Nephrology</i> , 2018, 50, 825-832.	0.6	9
138	Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 122-130.	0.6	24
139	Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β_3 -Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 158-166.	0.6	9
140	Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. <i>Neurourology and Urodynamics</i> , 2018, 37, 213-222.	0.8	10
141	MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxin-A injection. <i>Neurourology and Urodynamics</i> , 2018, 37, 99-105.	0.8	8
142	Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. <i>Journal of Urology</i> , 2018, 199, 229-236.	0.2	122
143	Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy?. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, 237-240.	0.6	1
144	Effects of urine alkalinization with sodium bicarbonate orally on lower urinary tract symptoms in female patients: a pilot study. <i>International Urogynecology Journal</i> , 2018, 29, 1029-1033.	0.7	4
145	Prospective Randomized Feasibility Study Assessing the Effect of Cyclic Sacral Neuromodulation on Urinary Urge Incontinence in Women. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, 267-271.	0.6	13
146	Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers: Are We Doing Enough?. <i>Journal of Urology</i> , 2018, 199, 779-784.	0.2	37
147	Female Urinary Incontinence. <i>Physician Assistant Clinics</i> , 2018, 3, 69-82.	0.1	1
148	Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2018, 24, 404-407.	0.6	13
149	Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. <i>Neurourology and Urodynamics</i> , 2018, 37, 986-996.	0.8	12
151	Sacral Nerve Stimulation as a Therapy for Patients With Refractory Voiding and Bowel Dysfunction. <i>Obstetrics and Gynecology</i> , 2018, 132, 1337-1345.	1.2	12
152	Individualizing medical treatment of overactive bladder. <i>Tzu Chi Medical Journal</i> , 2018, 30, 195.	0.4	2
153	Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience. <i>Urologia</i> , 2018, 85, 163-168.	0.3	2

#	ARTICLE	IF	CITATIONS
154	Sacral neuromodulation for treatment of overactive bladder: a review. , 2018, 97, 340-347.	0.0	0
155	Tibial Nerve and Sacral Neuromodulation in the Multiple Sclerosis Patient with Voiding Dysfunction. Current Bladder Dysfunction Reports, 2018, 13, 294-300.	0.2	1
156	Shared Pathophysiology of Detrusor Overactivity and Detrusor Underactivity. Current Bladder Dysfunction Reports, 2018, 13, 267-273.	0.2	1
157	Urothelial Senescence in the Pathophysiology of Diabetic Bladder Dysfunction—A Novel Hypothesis. Frontiers in Surgery, 2018, 5, 72.	0.6	13
159	Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost. Journal of the Turkish German Gynecology Association, 2018, 19, 7-10.	0.2	2
160	Re: Patterns of Medical Management of Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) in the United States. Journal of Urology, 2018, 200, 1170-1171.	0.2	0
161	Pharmacokinetics comparison of solifenacin tartrate and solifenacin succinate: a randomized, open-label, single-dose, 2-way crossover study in healthy male volunteers. Translational and Clinical Pharmacology, 2018, 26, 73.	0.3	1
162	Re: OnabotulinumtoxinA Detrusor Injection Improves Female Sexual Function in Women with Overactive Bladder Wet Syndrome. Journal of Urology, 2018, 200, 927-928.	0.2	0
163	Cardiovascular risk profile in individuals initiating treatment for overactive bladder — Challenges and learnings for comparative analysis using linked claims and electronic medical record databases. PLoS ONE, 2018, 13, e0205640.	1.1	5
164	What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?. Current Urology Reports, 2018, 19, 91.	1.0	3
165	Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia?. Journal of Clinical Medicine, 2018, 7, 263.	1.0	0
166	Management of Overactive Bladder in Older Women. Current Urology Reports, 2018, 19, 92.	1.0	30
167	Re: The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study. Journal of Urology, 2018, 200, 927-929.	0.2	0
168	Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?. European Urology Focus, 2018, 4, 760-767.	1.6	26
169	Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder. Medical Journal of Australia, 2018, 208, 41-45.	0.8	11
170	Can Lumbosacral Magnetic Resonance Imaging be Performed Safely in Patients with a Sacral Neuromodulation Device? An In Vivo Prospective Study. Journal of Urology, 2018, 200, 1088-1092.	0.2	21
171	Effects of an education program on toileting behaviors and bladder symptoms in overactive bladder patients with type 2 diabetes: A randomized clinical trial. International Journal of Nursing Studies, 2018, 87, 131-139.	2.5	13
172	Administration of leuprolide acetate, a GnRH agonist, improves urodynamic parameters in ovariectomized rats. Neurourology and Urodynamics, 2018, 37, 1574-1582.	0.8	3

#	ARTICLE	IF	CITATIONS
174	UDS in Overactive Bladder Syndrome (OAB-S). , 2018, , 131-147.		1
175	Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. <i>Toxins</i> , 2018, 10, 260.	1.5	14
176	Stress Urinary Incontinence Management in the Patient With Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2018, 13, 111-117.	0.2	0
177	Intravesical electrical stimulation treatment for overactive bladder: An observational study. <i>Investigative and Clinical Urology</i> , 2018, 59, 246.	1.0	5
178	Cost-Effectiveness of Third-Line Therapies for Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2018, 13, 153-157.	0.2	0
179	Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2018, 40, 225-231.	0.3	7
180	Cluster analysis of multiple chronic conditions associated with urinary incontinence among women in the USA. <i>BJU International</i> , 2018, 122, 1041-1048.	1.3	22
181	The Non-neurogenic Overactive Bladder: an Update. <i>Current Obstetrics and Gynecology Reports</i> , 2018, 7, 139-145.	0.3	1
182	Choosing oral drug therapy for overactive bladder in older people. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1375-1380.	0.9	7
184	How to report electrotherapy parameters and procedures for pelvic floor dysfunction. <i>International Urogynecology Journal</i> , 2018, 29, 1747-1755.	0.7	15
185	Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 252-259.	1.3	11
186	Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 768-778.e1.	2.3	17
187	What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICIâ€™ERS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S108-S116.	0.8	22
188	Anticholinergics for Overactive Bladder in Frail and Medically Complex Older People: The Case For. <i>Drugs and Aging</i> , 2018, 35, 777-780.	1.3	10
189	Mirabegron: A Review in Overactive Bladder Syndrome. <i>Drugs</i> , 2018, 78, 833-844.	4.9	44
190	Can surgical reconstruction of vaginal and ligamentous laxity cure overactive bladder symptoms in women with pelvic organ prolapse?. <i>BJU International</i> , 2019, 123, 493-510.	1.3	31
191	What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens. <i>International Urogynecology Journal</i> , 2019, 30, 701-704.	0.7	16
192	Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report. <i>Journal of Pediatric Surgery</i> , 2019, 54, 595-599.	0.8	11

#	ARTICLE	IF	CITATIONS
193	Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients. Journal of the Formosan Medical Association, 2019, 118, 279-284.	0.8	11
194	Agents in early development for treatment of bladder dysfunction – promise of drugs acting at TRP channels?. Expert Opinion on Investigational Drugs, 2019, 28, 749-755.	1.9	21
195	Systematic review of lower urinary tract symptoms occurring with pelvic organ prolapse. Arab Journal of Urology Arab Association of Urology, 2019, 17, 23-29.	0.7	8
196	What Is New in Neuromodulation?. Current Urology Reports, 2019, 20, 55.	1.0	11
197	Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment. European Urology, 2019, 76, 767-779.	0.9	19
198	Management of Overactive Bladder in the Young Man. Current Bladder Dysfunction Reports, 2019, 14, 205-213.	0.2	0
199	Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE. International Journal of Urology, 2019, 26, 890-896.	0.5	11
200	Clinical outcomes of percutaneous tibial nerve stimulation in elderly patients with overactive bladder. Arab Journal of Urology Arab Association of Urology, 2019, 17, 10-13.	0.7	6
201	Intraoperative Tips and Tricks for Successful Sacral Neuromodulation. Current Bladder Dysfunction Reports, 2019, 14, 191-196.	0.2	1
202	The real-life management of overactive bladder: Turkish Continence Society multicenter prospective cohort study with short-term outcome. Neurourology and Urodynamics, 2019, 38, 2170-2177.	0.8	2
203	Updating the evidence on drugs to treat overactive bladder: a systematic review. International Urogynecology Journal, 2019, 30, 1603-1617.	0.7	31
204	Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome. Toxins, 2019, 11, 586.	1.5	3
205	Stress urinary incontinence: An undertreated problem which deserves attention. Current Opinion in Biomedical Engineering, 2019, 11, 124-129.	1.8	0
206	Combination therapy in overactive bladder – untapped research opportunities: A systematic review of the literature. Neurourology and Urodynamics, 2019, 38, 2083-2092.	0.8	19
209	Initial Evaluation of a Novel Modulated Radiofrequency-based Bladder Denervation Device. Urology, 2019, 134, 237-242.	0.5	4
210	Comparative effectiveness of one versus two-stage sacral neurostimulation device placement. Neurourology and Urodynamics, 2019, 38, 734-739.	0.8	5
211	Recent Non-neurogenic Overactive Bladder Trials. Current Bladder Dysfunction Reports, 2019, 14, 18-23.	0.2	1
212	To stage or not to stage? – A cost minimization analysis of sacral neuromodulation placement strategies. Neurourology and Urodynamics, 2019, 38, 1783-1791.	0.8	5

#	ARTICLE	IF	CITATIONS
213	Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). <i>Advances in Therapy</i> , 2019, 36, 1906-1921.	1.3	12
214	The Current Role of Botox in a Pediatric Neurogenic Bladder Condition. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 115-123.	0.2	3
215	Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e026391.	0.8	53
216	Impact of LUTS on treatment-related behaviors and quality of life: A population-based study in Brazil. <i>Neurourology and Urodynamics</i> , 2019, 38, 1579-1587.	0.8	14
217	Factors associated with overactive bladder symptom improvement after 1 year of monthly percutaneous tibial nerve stimulation therapy. <i>Neurourology and Urodynamics</i> , 2019, 38, 1676-1684.	0.8	6
218	Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB). <i>Current Urology Reports</i> , 2019, 20, 33.	1.0	6
219	The combination of loratadine with famotidine to relieve the symptoms of urinary frequency in female patients with bladder function disorders: First report of three cases. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 796-799.	0.7	1
220	The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations. <i>Urology</i> , 2019, 130, 22-28.	0.5	5
221	Sacral neuromodulation for female pelvic floor disorders. <i>Arab Journal of Urology Arab Association of Urology</i> , 2019, 17, 14-22.	0.7	11
222	Current guidelines and treatment paradigms for nocturnal polyuria: A disease state for US physicians, patients and payers. <i>International Journal of Clinical Practice</i> , 2019, 73, e13337.	0.8	5
223	Pelvic floor dysfunction in midlife women. <i>Climacteric</i> , 2019, 22, 270-276.	1.1	25
224	Using a checklist to increase the effectiveness of behavioral therapy for overactive bladder: A prospective randomized controlled trial. <i>Neurourology and Urodynamics</i> , 2019, 38, 1152-1159.	0.8	4
225	Adjustment of Conditions for Combining Oxybutynin Transdermal Patch with Heparinoid Cream in Mice by Analyzing Blood Concentrations of Oxybutynin Hydrochloride. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 586-593.	0.6	3
226	The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. <i>Urology</i> , 2019, 127, 1-8.	0.5	14
227	Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 167, 155-160.	1.4	7
228	Transcutaneous posterior tibial nerve stimulation: Ready for prime time?. <i>Neurourology and Urodynamics</i> , 2019, 38, 1024-1025.	0.8	5
229	Use of Botulinum Toxin in the Genitourinary System. <i>Handbook of Experimental Pharmacology</i> , 2019, 263, 171-184.	0.9	4
230	New Implantable Tibial Nerve Stimulation Devices: Review of Published Clinical Results in Comparison to Established Neuromodulation Devices. <i>Research and Reports in Urology</i> , 2019, Volume 11, 351-357.	0.6	11

#	ARTICLE	IF	CITATIONS
231	Comparative Effectiveness of Transurethral Prostate Procedures at Enabling Urologic Medication Discontinuation: A Retrospective Analysis. <i>Urology</i> , 2019, 134, 192-198.	0.5	5
232	Effects and safety of herbal medicines on patients with overactive bladder. <i>Medicine (United States)</i> , 2019, 98, e17005.	0.4	1
234	Pelvic floor physical therapy in the treatment of pelvic floor dysfunction in women. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 485-493.	0.9	103
235	How can we better manage drug-resistant OAB/DO? ICIERS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S46-S55.	0.8	6
237	Efficacy and Safety of Noninvasive Intravesical Instillation of Onabotulinum Toxin-A for Overactive Bladder and Interstitial Cystitis/Bladder Pain Syndrome: Systematic Review and Meta-analysis. <i>Urology</i> , 2019, 125, 50-57.	0.5	6
238	A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAXOAB study. <i>Neurourology and Urodynamics</i> , 2019, 38, 689-695.	0.8	27
239	Diagnosis of Overactive Bladder. , 2019, , 261-261.		0
240	The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study. <i>International Urology and Nephrology</i> , 2019, 51, 27-32.	0.6	7
242	Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. <i>International Urogynecology Journal</i> , 2019, 30, 1253-1259.	0.7	21
243	Synthetic Midurethral Slings. <i>Urologic Clinics of North America</i> , 2019, 46, 17-30.	0.8	17
244	Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. <i>Neurourology and Urodynamics</i> , 2019, 38, 22-30.	0.8	27
245	Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial. <i>Neurourology and Urodynamics</i> , 2019, 38, 261-268.	0.8	78
246	Evaluation and treatment of female stress urinary incontinence after pelvic radiotherapy. <i>Neurourology and Urodynamics</i> , 2019, 38, S59-S69.	0.8	3
247	Intravesical Chemodenervation and Toxins. , 2019, , 177-204.		0
248	A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder. <i>Neurourology and Urodynamics</i> , 2019, 38, 660-667.	0.8	4
249	Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAIAll study). <i>International Journal of Urology</i> , 2019, 26, 342-352.	0.5	18
250	Cost-effectiveness of overactive bladder treatments: from the US payer perspective. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 61-71.	0.6	25
251	Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence. <i>Neurourology and Urodynamics</i> , 2019, 38, 825-837.	0.8	26

#	ARTICLE	IF	CITATIONS
253	Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 48-55.	0.6	74
254	In Search of Mobile Applications for Patients With Pelvic Floor Disorders. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2019, 25, 252-256.	0.6	13
255	Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation. <i>International Urogynecology Journal</i> , 2020, 31, 871-879.	0.7	6
256	Prevalence and clinical characteristics of overactive bladder in systemic sclerosis. <i>Modern Rheumatology</i> , 2020, 30, 327-331.	0.9	4
257	Patient navigation for overactive bladder improves access to care. <i>International Urogynecology Journal</i> , 2020, 31, 1007-1012.	0.7	9
258	Hypnotherapy or medications: a randomized noninferiority trial in urgency urinary incontinent women. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 159.e1-159.e16.	0.7	9
259	Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review. <i>Sexual Medicine</i> , 2020, 8, 1-7.	0.9	7
260	Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections?. <i>Neurourology and Urodynamics</i> , 2020, 39, 203-210.	0.8	11
261	Safety of Intradetrusor OnabotulinumtoxinA (BTX-A) Injection in the Asymptomatic Patient With a Positive Urine Dip. <i>Urology</i> , 2020, 135, 38-43.	0.5	6
262	A Preliminary Study on the Impact of Detrusor Overactivity on the Efficacy of Selective Bladder Denervation for the Treatment of Female Refractory Overactive Bladder. <i>Urology</i> , 2020, 136, 88-94.	0.5	1
263	Fibroid Surgery and Long-Term Improvement in Bladder Symptoms. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 131-136.	0.3	3
264	Management and treatment. , 2020, , 71-106.		0
265	Potential of Electrical Neuromodulation for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1119-1130.	0.9	28
266	A mobile telehealth program for behavioral treatment of urinary incontinence in women veterans: Development and pilot evaluation of MyHealthBladder. <i>Neurourology and Urodynamics</i> , 2020, 39, 432-439.	0.8	20
267	Comparison of Oral Sodium Bicarbonate and Solifenacin Treatment in Female Overactive Bladder Patients With Acidic Urine pH. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 649-653.	0.6	2
268	Are anticholinergic medications used for overactive bladder associated with new onset depression? A population-based matched cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1710-1714.	0.9	1
270	Association between lower urinary tract symptoms and cigarette smoking or alcohol drinking. <i>Translational Andrology and Urology</i> , 2020, 9, 312-321.	0.6	8
271	College Women's Experiences With Urinary Storage Symptoms. <i>Journal for Nurse Practitioners</i> , 2020, 16, 371-377.	0.4	4

#	ARTICLE	IF	CITATIONS
272	Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 224.	1.2	2
273	Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. <i>Scientific Reports</i> , 2020, 10, 11355.	1.6	4
274	The Role of Urodynamic Testing Prior to Third-Line OAB Therapy. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 159-165.	0.2	0
276	Contemporary Landmark Trials Update in the Management of Idiopathic Overactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 377-385.	0.2	1
278	Potential effectiveness of Ospemifene on Detrusor Overactivity in patients with vaginal atrophy. <i>Maturitas</i> , 2020, 138, 58-61.	1.0	8
279	Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?. <i>Current Urology Reports</i> , 2020, 21, 49.	1.0	10
280	Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States. <i>Neurourology and Urodynamics</i> , 2020, 39, 2206-2222.	0.8	8
281	Low-Intensity Extracorporeal Shock Wave Therapy Ameliorates the Overactive Bladder: A Prospective Pilot Study. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	12
282	Which combination is most effective in women with idiopathic overactive bladder, including bladder training, biofeedback, and electrical stimulation? A prospective randomized controlled trial. <i>Neurourology and Urodynamics</i> , 2020, 39, 2498-2508.	0.8	22
283	Taking OAB seriously: A qualitative evaluation of primary care education on overactive bladder syndrome management. <i>International Journal of Clinical Practice</i> , 2020, 74, e13604.	0.8	4
284	Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial. <i>BMC Urology</i> , 2020, 20, 129.	0.6	8
285	Treatment of Overactive Bladder in the Frail Patient. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 386-392.	0.2	0
286	Laser Acupuncture Alleviates Symptoms and Improves Quality of Life in Women with Overactive Bladder: A Double-Blind, Pilot Randomized Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-11.	0.5	7
287	Comparison of parasacral transcutaneous electrical stimulation and transcutaneous posterior tibial nerve stimulation in women with overactive bladder syndrome: A randomized clinical trial. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 250, 203-208.	0.5	11
288	Update on Implantable PTNS Devices. <i>Current Urology Reports</i> , 2020, 21, 28.	1.0	14
289	The clinical pharmacology of the medical treatment for overactive bladder in adults. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 707-720.	1.3	8
290	Effect of darifenacin on fecal incontinence in women with double incontinence. <i>International Urogynecology Journal</i> , 2021, 32, 2357-2363.	0.7	6
291	Optimizing Neuromodulation Testing—Who, When, and How?. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 153-158.	0.2	1

#	ARTICLE	IF	CITATIONS
292	A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients. <i>Toxins</i> , 2020, 12, 365.	1.5	2
293	Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-agonist: a population-based cohort study. <i>BJU International</i> , 2020, 126, 183-190.	1.3	65
294	Pelvic Floor, Urinary Problems and the Menopause. , 2020, , 112-123.		1
295	Urogynecologic pelvic floor problems: Across the entire spectrum of women's lives. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 169-171.	1.0	0
296	Is coexistent overactive/underactive bladder (with or without detrusor overactivity and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582 Td	0.8	17
297	EDITORIAL COMMENT. <i>Urology</i> , 2020, 136, 93-94.	0.5	0
298	A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. <i>Canadian Urological Association Journal</i> , 2020, 14, E297-E303.	0.3	12
299	Safety, Tolerability, Pharmacokinetics, and Food Effects on TAC-302 in Healthy Participants: Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Dose Studies. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 821-832.	0.8	1
300	Effectiveness of transcutaneous tibial nerve stimulation at two different thresholds for overactive bladder symptoms in older women: a randomized controlled clinical trial. <i>Maturitas</i> , 2020, 135, 40-46.	1.0	10
301	Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder. <i>Neurourology and Urodynamics</i> , 2020, 39, 1012-1019.	0.8	14
302	Patterns of Potentially Inappropriate Bladder Antimuscarinic Use in People with Dementia: A Retrospective Cohort Study. <i>Drugs - Real World Outcomes</i> , 2020, 7, 151-159.	0.7	7
303	Efficacy of Fractional CO ₂ Laser, Promestriene, and Vaginal Lubricant in the Treatment of Urinary Symptoms in Postmenopausal Women: A Randomized Clinical Trial. <i>Lasers in Surgery and Medicine</i> , 2020, 52, 713-720.	1.1	36
304	Female Pelvic Surgery. , 2020, , .		0
305	Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men. <i>JAMA Internal Medicine</i> , 2020, 180, 411.	2.6	41
306	Vitamin D intake and the 10-year risk of urgency urinary incontinence in women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 199, 105601.	1.2	9
307	Evaluation and Treatment of Overactive Bladder in Women. <i>Mayo Clinic Proceedings</i> , 2020, 95, 370-377.	1.4	39
309	Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder. <i>Frontiers in Pharmacology</i> , 2019, 10, 1618.	1.6	14
310	Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. <i>Neurourology and Urodynamics</i> , 2020, 39, 1108-1114.	0.8	12

#	ARTICLE	IF	CITATIONS
311	Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0230355.	1.1	8
312	Female Lower Urinary Tract Symptom Prevention and Treatment Strategies on Social Media: Mixed Correlation With Evidence. Urology, 2021, 150, 139-145.	0.5	5
313	Inhibitory effects of a minimally invasive implanted tibial nerve stimulation device on non-nociceptive bladder reflexes in cats. International Urology and Nephrology, 2021, 53, 431-438.	0.6	2
314	The Correlation between Severity of Overactive Bladder Symptoms with Female Sexual Dysfunction and Sexual Satisfaction of Partners. Urologia Internationalis, 2021, 105, 124-130.	0.6	7
315	National Trends in Neuromodulation for Urinary Incontinence Among Insured Adult Women and Men, 2004-2013: The Urologic Diseases in America Project. Urology, 2021, 150, 86-91.	0.5	3
316	Does symptom severity predict response to low-dose onabotulinumtoxinA for the treatment of urgency urinary incontinence?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 118-124.	0.5	1
317	National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, e261-e266.	0.6	25
318	Overview of Treatment of Urinary Incontinence. , 2021, , 75-94.		0
319	Detrusor Overactivity with Detrusor Underactivity. Urodynamics, Neurourology and Pelvic Floor Dysfunctions, 2021, , 139-148.	0.0	0
320	Effect of diet on storage symptoms in male lower urinary tract symptoms. , 2021, , 177-187.		0
321	Variable- versus constant-frequency sacral neuromodulation in black-zone overactive bladder patients: a study protocol for a multicenter, prospective, randomized, blind, self-controlled trial. Translational Andrology and Urology, 2021, 10, 504-511.	0.6	3
322	AIM in Oncology. , 2021, , 1-11.		0
323	Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Scientific Reports, 2021, 11, 914.	1.6	32
324	Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 69-71.	0.6	21
325	Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. The Cochrane Library, 2021, 2021, CD012336.	1.5	5
326	Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. International Urogynecology Journal, 2022, 33, 703-709.	0.7	6
327	Can We Rely Solely on the International Prostate Symptoms Score to Investigate Storage Symptoms in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement? Findings from a Cross-sectional Study. European Urology Focus, 2021, , .	1.6	0
328	Feasibility and Effectiveness of an Interprofessional Mindfulness-Informed Group-Based Intervention for Treatment of Overactive Bladder: A Pilot Study. Journal of Women's Health Physical Therapy, 2021, 45, 76-82.	0.5	0

#	ARTICLE	IF	CITATIONS
329	Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk. <i>International Urogynecology Journal</i> , 2021, 32, 2819-2826.	0.7	13
330	Comparison of 100 U With 200 U of Intradetrusor OnabotulinumToxinA for Nonneurogenic Urgency Incontinence. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2021, 27, 140-146.	0.6	2
331	Male Overactive Bladder: Underappreciated, Under-researched. More Please?. <i>European Urology</i> , 2021, 79, 505-506.	0.9	2
332	Adult female urinary incontinence guidelines: a systematic review of evaluation guidelines across clinical specialties. <i>International Urogynecology Journal</i> , 2021, 32, 2671-2691.	0.7	1
333	Evaluation of the relationship of cholinergic metabolites in urine and urgency urinary incontinence. <i>International Urogynecology Journal</i> , 2022, 33, 1165-1174.	0.7	1
334	Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. <i>European Urology</i> , 2021, 79, 492-504.	0.9	20
335	Is a 50% improvement threshold adequate to justify progression from sacral neuromodulation testing to implant?. <i>Neurourology and Urodynamics</i> , 2021, 40, 1524-1531.	0.8	3
336	Treatment for overactive bladder. <i>Medicine (United States)</i> , 2021, 100, e25941.	0.4	9
337	Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder. <i>Therapeutic Delivery</i> , 2021, 12, 353-362.	1.2	0
338	The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy. <i>Spinal Cord Series and Cases</i> , 2021, 7, 50.	0.3	8
339	Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2021, 27, 481-487.	0.6	0
340	Gene Therapy for Overactive Bladder: A Review of BK-Channel $\hat{\pm}$ -Subunit Gene Transfer. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 589-599.	0.9	11
341	Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial. <i>International Urology and Nephrology</i> , 2021, 53, 2243-2250.	0.6	3
342	Axonics [®] system for treatment of overactive bladder syndrome and urinary urgency incontinence. <i>Expert Review of Medical Devices</i> , 2021, 18, 727-732.	1.4	1
343	Hip and Pelvic Floor Muscle Strength in Women With and Without Urgency and Frequency-Predominant Lower Urinary Tract Symptoms. <i>Journal of Women's Health Physical Therapy</i> , 2021, 45, 126-134.	0.5	7
344	A systematic review of neurocognitive dysfunction with overactive bladder medications. <i>International Urogynecology Journal</i> , 2021, 32, 2693-2702.	0.7	20
345	Association between the Trp64Arg polymorphism of the ADRB3 gene and overactive bladder. <i>Neurourology and Urodynamics</i> , 2021, 40, 1780-1785.	0.8	6
346	Real-world Compliance With Percutaneous Tibial Nerve Stimulation Maintenance Therapy in an American Population. <i>Urology</i> , 2021, 153, 119-123.	0.5	9

#	ARTICLE	IF	CITATIONS
347	Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2021, 27, 450-456.	0.6	5
348	The cognitive effect of anticholinergics for patients with overactive bladder. <i>Nature Reviews Urology</i> , 2021, 18, 686-700.	1.9	32
349	Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder. <i>Drugs and Aging</i> , 2021, 38, 911-920.	1.3	3
351	Movement Impairments in Women With and Without Urinary Urgency/Frequency. <i>Journal of Women's Health Physical Therapy</i> , 2021, Publish Ahead of Print, 164-173.	0.5	3
352	Efficacy of non-pharmacological interventions in patients with overactive bladder: A protocol for systematic review and network meta-analysis. <i>Nursing Open</i> , 2021, , .	1.1	1
353	SUFU reduced pancreatic cancer cell growth by Wnt/ β -catenin signaling pathway. <i>Food Science and Technology</i> , 0, , .	0.8	0
354	The impact of myasthenia gravis on lower urinary tract functions. <i>International Journal of Clinical Practice</i> , 2021, , e14873.	0.8	1
355	Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2022, 57, .	1.0	8
356	Regulation of P2X1 receptors by modulators of the cAMP effectors PKA and EPAC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2108094118.	3.3	7
357	Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review. <i>International Neurourology Journal</i> , 2021, 25, 182-191.	0.5	5
358	Intravaginal electrical stimulation for bladder training method. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 1160-1161.	0.7	2
359	Efficacy of intravaginal electrical stimulation added to bladder training in women with idiopathic overactive bladder: A prospective randomized controlled trial. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 1150-1159.	0.7	15
360	Current pharmacotherapy of overactive bladder. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 1091-1107.	0.7	13
361	Basic Evaluation of the Patient with Pelvic Floor Dysfunction (General Review). , 2021, , 3-16.		0
362	Efficacy of magnetic stimulation for female stress urinary incontinence: a meta-analysis. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110324.	0.9	7
363	Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice. <i>Tzu Chi Medical Journal</i> , 2022, 34, 441.	0.4	3
364	Posterior Tibial Nerve Stimulation. , 2018, , 131-141.		3
365	A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection. <i>International Urogynecology Journal</i> , 2020, 31, 1907-1912.	0.7	11

#	ARTICLE	IF	CITATIONS
366	Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. <i>Urology</i> , 2020, 142, 87-93.	0.5	5
367	Incontinence after Prostate Treatment: AUA/SUFU Guideline. <i>Journal of Urology</i> , 2019, 202, 369-378.	0.2	134
368	Clinical outcomes of sacral neuromodulation in non-neurogenic, non-obstructive dysuria: A 5-year retrospective, multicentre study in China. <i>World Journal of Clinical Cases</i> , 2020, 8, 2494-2501.	0.3	3
369	Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. <i>PLoS ONE</i> , 2017, 12, e0175335.	1.1	22
370	The Urological Society of India survey on urinary incontinence practice patterns among urologists. <i>Indian Journal of Urology</i> , 2018, 34, 202.	0.2	5
371	Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence. <i>Tzu Chi Medical Journal</i> , 2017, 29, 72.	0.4	4
372	Traditional Chinese Medicine and Herbal Supplements for Treating Overactive Bladder. <i>Urological Science</i> , 2018, 29, 216-222.	0.2	8
373	Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. <i>Investigative and Clinical Urology</i> , 2020, 61, S33.	1.0	33
374	Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. <i>Investigative and Clinical Urology</i> , 2020, 61, 600.	1.0	1
375	The attitudes of Urologists and Gynecologists about overactive bladder and treatment of it in Turkey: A questionnaire survey. <i>Turkish Journal of Urology</i> , 2017, 43, 68-74.	1.3	6
376	Predictors of Nerve Stimulator Success in Patients With Overactive Bladder. <i>International Neurourology Journal</i> , 2018, 22, 206-211.	0.5	6
377	Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation. <i>International Neurourology Journal</i> , 2019, 23, 226-233.	0.5	6
378	Do Failure of Posterior Tibial Nerve Stimulation Precludes to Use Sacral Neuromodulation in Patient With Overactive Bladder?. <i>International Neurourology Journal</i> , 2019, 23, 287-293.	0.5	5
379	Transcutaneous tibial nerve stimulation versus parasacral stimulation in the treatment of overactive bladder in elderly people: a triple-blinded randomized controlled trial. <i>Clinics</i> , 2020, 75, e1477.	0.6	20
380	<i>De Novo</i> Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors. <i>Journal of Urology</i> , 2022, 207, 601-608.	0.2	5
381	Effect of vitamin D supplementation on urinary incontinence in older women: ancillary findings from a randomized trial. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 535.e1-535.e12.	0.7	7
382	Current advances in neuromodulation techniques in urology practices: A review of literature. , 2021, 47, 375-385.		5
383	Percutaneous Tibial Nerve Stimulation. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
384	Men Have Bladders, Too. , 2016, , 187-205.		0
385	Management of Genitourinary Syndrome of Menopause (GSM). , 2017, , 129-144.		0
386	Synthetic Midurethral Slings: Urinary Tract Sequelae. Current Clinical Urology, 2017, , 165-176.	0.0	0
387	ThÃ©rapies comportementales et cognitives pour une incontinence urinaire fÃ©minine. , 2017, , 107-110.		0
388	Applications of Botulinum Toxin in the Urinary Tract. , 2018, , 49-65.		0
391	Optimization of treatment idiopathic overactive bladder without detrusor overactivity. Health of Man, 2018, .	0.1	0
392	Behavioral Therapy in Combination with Pharmacotherapy. , 2019, , 149-161.		0
393	Individualizing Drug Therapy. , 2019, , 291-314.		0
394	Percutaneous tibial nerve stimulation associated with occipital headaches: a review of the adverse effects of percutaneous tibial nerve stimulation. Obstetrics & Gynecology International Journal, 2018, 9, .	0.0	0
395	The Modulation Of Detrusor Contractility By Agents Influencing Ion Channel Activity. European Pharmaceutical Journal, 2018, 65, 8-11.	0.2	0
396	Management of Overactive Bladder. , 2019, , 263-263.		0
397	Overactive Bladder. , 2019, , 257-259.		0
398	Urine-incontinentie bij ouderen. Praktische Huisartsgeneeskunde, 2020, , 359-378.	0.0	0
399	FEATURES TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY. Likars'ka Sprava, 2019, , 35-40.	0.2	0
400	Fesoterodine experience in women with overactive bladder syndrome. Experimental and Clinical Urology, 2019, 11, 146-150.	0.0	0
401	OVERACTIVE BLADDER. World Science, 2020, 1, 15-19.	0.0	0
402	Editorial Comment: Does pre-operative urodynamics lead to better outcomes in management of urinary incontinence in women? A linked systematic review and meta-analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 471-472.	0.7	0
403	Refractory bladder dysfunction: A multi-institutional experience with intravesical botulinum toxin-a injection in adult patients who underwent previous augmentation cystoplasty. Turkish Journal of Urology, 2020, 46, 309-313.	1.3	4

#	ARTICLE	IF	CITATIONS
404	Editorial Comment: Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 669-670.	0.7	0
405	The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications. <i>Neurourology and Urodynamics</i> , 2022, 41, 348-356.	0.8	15
406	Botulinum Toxin Therapy for Voiding Dysfunction. , 2020, , 255-282.		0
407	Neuromodulation for Voiding Dysfunction. , 2020, , 49-64.		0
408	Intravesical Botulinum Toxin for the Treatment of Overactive Bladder. , 2021, , 365-373.		0
409	Variable frequency stimulation of sacral neuromodulation in black-zone overactive bladder patients: a case report. <i>Translational Andrology and Urology</i> , 2020, 9, 2842-2847.	0.6	2
410	Progress in research of sacral nerve stimulation. <i>World Chinese Journal of Digestology</i> , 2020, 28, 1266-1271.	0.0	1
411	Improvement of health-related quality of life in patients with overactive bladder syndrome: A subanalysis of the prospective, noninterventional study BELIEVE in the Greek population. <i>Hellenic Urology</i> , 2020, 32, 135.	0.1	0
412	Diagnosis, assessment, and examination. , 2020, , 41-69.		4
413	Botulinum Toxin Treatment in Urological Disorders. , 2020, , 297-308.		0
414	Overactive Bladder. , 2020, , 287-307.		0
415	Urinary Incontinence in Palliative Care Settings: Part 2: Management #426. <i>Journal of Palliative Medicine</i> , 2021, 24, 1734-1735.	0.6	3
416	A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA. <i>Drugs and Aging</i> , 2021, 38, 1075-1085.	1.3	5
418	Impact of urodynamic evaluation on the treatment of women with idiopathic overactive bladder: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 420-426.	3.9	7
419	Pharmacological monitoring of the clinical course of an overactive bladder without urinary incontinence. <i>Urology</i> , 2020, 24, .	0.1	0
420	Radical Prostatectomy and Survivorship After Radical Prostatectomy. , 2021, , 29-41.		0
421	The Role of Apoptosis in Detrusor Contractility. <i>International Neurourology Journal</i> , 2020, 24, 67-71.	0.5	1
422	Interactions between Drugs and Surgery in the Treatment of LUTS and Advanced Renal Cancer. <i>Current Drug Targets</i> , 2020, 21, 1512-1514.	1.0	1

#	ARTICLE	IF	CITATIONS
423	Nocturia in Patients With Multiple Sclerosis. <i>Reviews in Urology</i> , 2019, 21, 63-73.	0.9	4
425	Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. <i>Annals of Physical and Rehabilitation Medicine</i> , 2022, 65, 101486.	1.1	21
427	The Impact of Provider Sex and Experience on the Quality of Care Provided for Women with Urinary Incontinence. <i>American Journal of Medicine</i> , 2022, 135, 524-530.e1.	0.6	3
428	Prevalence and predictors of nocturnal polyuria in females with overactive bladder syndrome. <i>World Journal of Urology</i> , 2021, , 1.	1.2	2
429	Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome. <i>Medicine (United States)</i> , 2021, 100, e27745.	0.4	1
430	Female Urinary Incontinence Evidence-Based Treatment Pathway: An Infographic for Shared Decision-Making. <i>Journal of Women's Health</i> , 2022, 31, 341-346.	1.5	8
431	The effect of amino acids on the bladder cycle: a concise review. <i>Amino Acids</i> , 2022, 54, 13-31.	1.2	0
432	Predicting outcomes after intradetrusor onabotulinumtoxinA for non-neurogenic urgency incontinence in women. <i>Neurourology and Urodynamics</i> , 2022, 41, 432-447.	0.8	9
433	Mirabegron versus Solifenacine in Treatment of Overactive Bladder in Female Patients in Zagazig University Hospitals. <i>The Egyptian Journal of Hospital Medicine</i> , 2020, 81, 2078-2083.	0.0	0
434	A Comparative Study of Efficacy and Tolerability of Solifenacin and Mirabegron, for the Treatment of Overactive Bladder - A Randomized Prospective Control Study. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2021, 10, 3654-3658.	0.1	0
435	OUP accepted manuscript. <i>Age and Ageing</i> , 2022, 51, .	0.7	1
436	The Association Between Urinary Tract Infection and Overactive Bladder Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 803970.	1.6	1
438	Electrochemical Determination of Mirabegron at Silica Modified Carbon Paste in Micellar Medium: Sensitive Application with Drug Product and Spiked Plasma. <i>ChemistrySelect</i> , 2022, 7, .	0.7	3
440	Gastroenterological disorders increase the prevalence of overactive bladder in females at various ages. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 84-87.	0.0	0
441	An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders. <i>International Urology and Nephrology</i> , 2022, 54, 479-491.	0.6	4
442	Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: A systematic review and meta-analysis. <i>Neurourology and Urodynamics</i> , 2022, 41, 539-551.	0.8	9
443	Physiotherapeutic assessment and management of overactive bladder syndrome: a case report. <i>Physiotherapy Theory and Practice</i> , 2022, , 1-8.	0.6	0
444	Translation and validation of the Portuguese version of the International Consultation on Incontinence Questionnaire (ICIQ) Bladder Diary. <i>International Urogynecology Journal</i> , 2022, , 1.	0.7	3

#	ARTICLE	IF	CITATIONS
445	Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit. <i>Biomedicines</i> , 2022, 10, 270.	1.4	3
446	Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects. <i>Expert Review of Medical Devices</i> , 2022, 19, 161-187.	1.4	7
447	The effectiveness of different electrical nerve stimulation protocols for treating adults with non-neurogenic overactive bladder: a systematic review and meta-analysis. <i>International Urogynecology Journal</i> , 2022, 33, 1045-1058.	0.7	4
448	Botulinum toxin for treating overactive bladder in men: A systematic review. <i>Neurourology and Urodynamics</i> , 2022, 41, 710-723.	0.8	9
449	Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment. <i>Biomedicines</i> , 2022, 10, 396.	1.4	11
450	Irregular bladder shapes identified in women with overactive bladder: an ultrasound nomogram. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 367-377.	0.4	2
451	AIM in Oncology. , 2022, , 1263-1273.		0
452	The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis. <i>Tzu Chi Medical Journal</i> , 2023, 35, 31.	0.4	5
453	Overactive bladder (OAB): a failed concept needing revision to accommodate an external anatomical control system. <i>World Journal of Urology</i> , 2022, , 1.	1.2	2
454	Frequency of overactive bladder (OAB) and the factors affecting it in patients with obstructive sleep apnea syndrome (OSAS). <i>Urologia</i> , 2022, , 039156032210782.	0.3	1
455	Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Frontiers in Pharmacology</i> , 2022, 13, 840695.	1.6	3
456	Continuing posterior tibial nerve stimulation after twelve weekly sessions: a randomized controlled trial. <i>Urogynaecologia International Journal</i> , 2022, 34, .	0.2	0
457	ADRB3, ROCK2, and GEF Levels in Overactive Bladder Patients. <i>International Neurourology Journal</i> , 2022, 26, S8-14.	0.5	1
458	Botulinum Neurotoxin Uses in Overactive Bladder. , 0, , .		0
459	Delivering patient-centered care through shared decision making in overactive bladder. <i>Neurourology and Urodynamics</i> , 2022, 41, 884-893.	0.8	5
460	Prevalence of Overactive Bladder Symptoms Among Women With Interstitial Cystitis/Bladder Pain Syndrome. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2022, 28, e115-e119.	0.6	2
461	New Frontiers of Extracorporeal Shock Wave Medicine in Urology from Bench to Clinical Studies. <i>Biomedicines</i> , 2022, 10, 675.	1.4	12
462	Why Patients Fall Through the Cracks: Assessment of Patients' Overactive Bladder Treatment. <i>Journal of Women's Health</i> , 2022, 31, 1314-1319.	1.5	3

#	ARTICLE	IF	CITATIONS
463	What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine. <i>Advances in Therapy</i> , 2022, 39, 2489-2501.	1.3	5
464	RESPONSE TO THE AUTHORS "Intravaginal electrical stimulation for bladder training method" by Cássio L. Z. Ricetto, 2021. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 375-376.	0.7	0
465	Correlación del grosor de la pared vesical con síndrome de vejiga hiperactiva y hallazgos urodinámicos. <i>Revista Mexicana De Urologia</i> , 2021, 81, 1-11.	0.0	0
466	Reoperative Anti-incontinence Surgery. <i>Current Bladder Dysfunction Reports</i> , 2022, 17, 20-29.	0.2	0
467	Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-9.	0.8	4
468	Re: Efficacy and safety of intradetrusor botulinum toxin injections for idiopathic overactive bladder syndrome in patients with an artificial urinary sphincter. <i>World Journal of Urology</i> , 2022, , .	1.2	0
469	Clinical Utility of β -Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations. <i>Research and Reports in Urology</i> , 2022, Volume 14, 167-175.	0.6	2
470	A Multi-Center, Randomized, Blind, Controlled Clinical Trial of the Safety and Efficacy of Micro Radio Frequency Therapy System for the Treatment of Overactive Bladder. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	2
471	Combination and Novel Pharmacologic Agents for OAB. <i>Current Urology Reports</i> , 2022, , 1.	1.0	0
472	Efecto de la electroestimulación del nervio tibial en la musculatura del piso pélvico de pacientes con síndrome de vejiga hiperactiva. <i>Revista Mexicana De Urologia</i> , 2019, 79, 1-11.	0.0	0
473	Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210981.	0.4	1
474	Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome. <i>Neurourology and Urodynamics</i> , 2022, 41, 1958-1966.	0.8	8
475	Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. <i>Minerva Urology and Nephrology</i> , 2023, 74, .	1.3	5
476	Non-inferior and more feasible transcutaneous tibial nerve stimulation in treating overactive bladder: A systematic review and meta-analysis. <i>International Journal of Urology</i> , 2022, 29, 1170-1180.	0.5	4
477	Biofeedback-assisted pelvic floor muscle training and pelvic electrical stimulation in women with overactive bladder: A systematic review and meta-analysis of randomized controlled trials. <i>Neurourology and Urodynamics</i> , 2022, 41, 1258-1269.	0.8	5
478	Regarding the readability of online resources for third-line treatment of overactive bladder in the US population based on Werner et al's study. <i>International Urogynecology Journal</i> , 2022, 33, 2071-2072.	0.7	0
479	Nano-BTA: A New Strategy for Intravesical Delivery of Botulinum Toxin A. <i>International Neurourology Journal</i> , 2022, 26, 92-101.	0.5	1
480	Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?. <i>Toxins</i> , 2022, 14, 498.	1.5	8

#	ARTICLE	IF	CITATIONS
481	Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	3
483	Busting for change: a care pathway for overactive bladder. <i>Trends in Urology & Men's Health</i> , 2022, 13, 17-21.	0.2	1
484	Neural networks outperform expert humans in predicting patient impressions of symptomatic improvement following overactive bladder treatment. <i>International Urogynecology Journal</i> , 2023, 34, 1009-1016.	0.7	1
485	Effects of transcutaneous tibial nerve stimulation on females with overactive bladder syndrome in multiple sclerosis a protocol for a systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0269371.	1.1	1
486	Pharmacistâ€driven interventions to deâ€escalate urinary antimuscarinics in the Programs of Allâ€Inclusive Care for the Elderly. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 3230-3238.	1.3	6
487	Current State of Non-surgical Devices for Female Stress Urinary Incontinence. <i>Current Urology Reports</i> , 2022, 23, 185-194.	1.0	1
488	The use of botulinum toxin (BoNT) in urology - review. <i>Journal of Education, Health and Sport</i> , 2022, 12, 1026-1036.	0.0	0
489	Gender differences in the experience of interstitial cystitis/bladder pain syndrome. <i>Frontiers in Pain Research</i> , 0, 3, .	0.9	5
490	Potential role of oxidative stress in the pathogenesis of diabetic bladder dysfunction. <i>Nature Reviews Urology</i> , 2022, 19, 581-596.	1.9	13
491	Factors predicting the treatment success of bladder training for urgency urinary incontinence. <i>Neurourology and Urodynamics</i> , 0, , .	0.8	2
492	Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labelled Study. <i>Yonago Acta Medica</i> , 2022, 65, 231-237.	0.3	0
493	Urgency and urgency incontinence following stress urinary incontinence surgery: A review of evaluation and management. <i>Indian Journal of Urology</i> , 2022, 38, 268.	0.2	3
494	Vitamin D supplements and prevalent overactive bladder in women from midlife through older ages. <i>Menopause</i> , 0, Publish Ahead of Print, .	0.8	0
495	Phenotyping of Urinary Urgency Patients Without Urgency Incontinence, and Their Comparison to Urgency Incontinence Patients: Findings From the LURN Study. <i>Journal of Urology</i> , 2023, 209, 233-242.	0.2	1
496	Relationship Between Marijuana Use and Overactive Bladder (OAB): A Cross-Sectional Research of NHANES 2005 to 2018. <i>American Journal of Medicine</i> , 2023, 136, 72-78.	0.6	5
497	Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population. <i>Neurourology and Urodynamics</i> , 2022, 41, 1872-1889.	0.8	4
498	Comparing clinical bladder diaries and recalled patient reports for measuring lower urinary tract symptoms in the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). <i>Neurourology and Urodynamics</i> , 2022, 41, 1711-1721.	0.8	5
499	Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial. <i>Journal of Urology</i> , 2023, 209, 243-252.	0.2	2

#	ARTICLE	IF	CITATIONS
500	Treatment patterns in women with urinary urgency and/or urgency urinary incontinence in the symptoms of Lower Urinary Tract Dysfunction Research Network Observational Cohort Study. <i>Neurourology and Urodynamics</i> , 2023, 42, 194-204.	0.8	1
501	Novel botulinum neurotoxin-A tibial nerve perineural injection to alleviate overactive bladder symptoms in male rats. <i>Animal Cells and Systems</i> , 2022, 26, 283-290.	0.8	0
502	Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
503	The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia. <i>European Urology Open Science</i> , 2022, 46, 22-29.	0.2	2
504	Comparison of Two Treatment Modalities in Overactive Bladder: a Rapid Overview. <i>Medicinski Arhiv = Medical Archives = Archives De MÃ©decine</i> , 2022, 76, 469.	0.4	0
505	Evidence-Informed, Interdisciplinary, Multidimensional Action Plan to Advance Overactive Bladder Research and Treatment Initiatives: Directives From State-of-the-Science Conference on Overactive Bladder and Cognitive Impairment. , 2023, 29, S20-S39.		6
506	Comparison of the Effect of Oral Sodium Bicarbonate and Tolterodine in Women with Symptoms of Overactive Bladder with Acidic Urine- A Single-Blind Randomized Clinical Trial. <i>Current Women's Health Reviews</i> , 2023, 19, .	0.1	0
507	OnabotulinumtoxinA discontinuation in patients with prior nerve stimulation. <i>Neurourology and Urodynamics</i> , 0, , .	0.8	0
508	Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders. <i>Toxins</i> , 2022, 14, 838.	1.5	2
509	Physical and Rehabilitation Therapy for Overactive Bladder in Women: A Systematic Review and Meta-Analysis. <i>International Journal of Clinical Practice</i> , 2023, 2023, 1-10.	0.8	2
510	Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients. <i>Tzu Chi Medical Journal</i> , 2023, 35, 62.	0.4	4
511	The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years. <i>Cureus</i> , 2023, , .	0.2	1
512	MESANE PATOLOJÄ°LERÄ°NDE BOTULÄ°NUM TOKSÄ°N UYGULAMALARI: Ä°LK HASTA SERÄ°SÄ° SONUÄ°LARIMIZ. <i>Ankara EÄ°yitim Ve AraÄ°tÄ±rma Hastanesi TÄ±p Dergisi</i> , 0, , .	0.1	0
513	Development of an implant technique and early experience using a novel implantable pulse generator with a quadripolar electrode array at the tibial nerve for refractory overactive bladder. <i>Neurourology and Urodynamics</i> , 2023, 42, 427-435.	0.8	1
514	Insights from the AQUA Registry: a retrospective study of anticholinergic polypharmacy in the United States. <i>Therapeutic Advances in Urology</i> , 2023, 15, 175628722211505.	0.9	1
515	Effect of Neuro-Adaptive Electrostimulation Therapy versus Sham for Refractory Urge Urinary Incontinence due to Overactive Bladder: A Randomized Single-Blinded Trial. <i>Journal of Clinical Medicine</i> , 2023, 12, 759.	1.0	0
516	Pre- versus Post-Menopausal Onset of Overactive Bladder and the Response to Vaginal Estrogen Therapy: A Prospective Study. <i>Medicina (Lithuania)</i> , 2023, 59, 245.	0.8	0
517	Overactive Bladder. , 2023, , 255-261.		0

#	ARTICLE	IF	CITATIONS
518	Despite Recommendations, Anticholinergics Account for the Majority of Prescriptions to Treat Overactive Bladder in the United States. , 2023, 29, 497-503.		1
519	Perioperative Techniques for the Use of Botulinum Toxin in Overactive Bladder: Results of a Multinational Online Survey of Urogynecologists in Germany, Austria, and Switzerland. Journal of Clinical Medicine, 2023, 12, 1462.	1.0	0
520	Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinsonâ€™s Disease or Post-Stroke. Toxins, 2023, 15, 166.	1.5	5
521	Bladder Dysfunction and Pelvic Pain: The Role of Sacral, Tibial, and Pudendal Neuromodulation. , 2022, , 1-19.		0
522	Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. LUTS: Lower Urinary Tract Symptoms, 2023, 15, 80-88.	0.6	2
523	Telemedicine in Overactive Bladder Syndrome. Current Bladder Dysfunction Reports, 0, , .	0.2	0
524	Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study. Frontiers in Neuroscience, 0, 17, .	1.4	0
525	Acupuncture for Women with Overactive Bladder: Perspective of Traditional Chinese Medicine and Related Mechanism. International Journal of General Medicine, 0, Volume 16, 1137-1148.	0.8	3
526	Effectiveness of Fluid and Caffeine Modifications on Symptoms in Adults With Overactive Bladder: A Systematic Review. International Neurourology Journal, 2023, 27, 23-35.	0.5	0
528	Treating Incontinence for Underlying Mental and Physical Health (TRIUMPH): a study protocol for a multicenter, double-blinded, randomized, 3-arm trial to evaluate the multisystem effects of pharmacologic treatment strategies for urgency-predominant urinary incontinence in ambulatory older women. Trials, 2023, 24, .	0.7	0
534	Efficacy and safety of vaginal electrical stimulation as an alternative or adjunct treatment for overactive bladder syndrome in women: a meta-analysis of randomized controlled trials. International Urogynecology Journal, 0, , .	0.7	0
540	Bladder Dysfunction and Pelvic Pain: The Role of Sacral, Tibial, and Pudendal Neuromodulation. , 2023, , 255-273.		1